Open AccessMOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study
Author(s) -
Marc S. Raab,
Manik Chatterjee,
Hartmut Goldschmidt,
Hermine Agis,
Igor W. Blau,
Hermann Einsele,
Monika Engelhardt,
Barbara Ferstl,
Martin Gramatzki,
Christoph Röllig,
Katja Weisel,
Tiantom Jarutat,
Dominika Weinelt,
Mark Winderlich,
Christian Peschel
Publication year - 2018
Publication title -
blood
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.515
H-Index - 465
eISSN - 1528-0020
pISSN - 0006-4971
DOI - 10.1182/blood-2018-153
Subject(s) - pomalidomide , lenalidomide , medicine , dexamethasone , multiple myeloma , daratumumab , pharmacology , neutropenia , oncology , toxicity
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom